Skip to main content
Ebola vaccine

Coronavirus and Ebola Show We Can’t Leave Vaccine Development to Big Pharma

Juliana Broad writes about the botched development of the Ebola vaccine, citing the work of The Democracy Collaborative’s Dana Brown on the necessity of public pharma.

Five years after an Ebola epidemic killed more than 11,000 people across West Africa, the U.S. Food and Drug Administration announced at the end of December 2019 that Merck, the behemoth, for-profit pharmaceutical company based in New Jersey, had received approval for an Ebola vaccine.

But this is hardly a success story. In fact, the saga behind the vaccine’s development sheds light on how involving private pharmaceutical companies may have obstructed the vaccine’s progress, profiting from publicly funded research only once the vaccine’s development proved to be lucrative business.

A new report, published in the Journal of Law and the Biosciences, details how the Ebola vaccine, Ervebo, was almost entirely researched and developed using public money, challenging the common assumption that only private, profit-driven companies are able to bring drugs to market.

Matthew Herder, one of the authors of the report, noted parallels between the Ebola response and the current coronavirus outbreak. “It seems fairly clear that the same approach — of patenting and licensing out to the private sector — is being relied upon by the public sector to advance vaccine development,” he told Truthout via email.

Herder emphasizes that their case study on Ebola cannot be generalized. Nonetheless, the authors raise a particularly urgent question as the U.S. struggles to marshal a response to a spreading coronavirus outbreak: Could the Ebola vaccine have been produced earlier, potentially saving thousands of lives, if researchers could have avoided the profit-driven trappings of private pharmaceutical companies?

Read the entire article at Truthout.

Publication date: 2020-03-09
Parent publication: Truthout
Publication URL: https://truthout.org/articles/coronavirus-and-ebola-show-we-cant-leave-vaccine-development-to-big-pharma/

More related work

March 19, 2020
Default Image

Protect the vulnerable, advance the democratic economy: Our statement on the COVID-19 crisis

We are in a period of breakdown, in which all that is wrong with the current system is now being laid bare. Rather than rebuild what we now clearly see should never have been, we must lead the construction out of this crisis of something new.

read more
March 18, 2020
Default Image

HAN Public Comments on Fair Housing Act Proposed Changes

The Healthcare Anchor Network submitted public comments to the Department of Housing and Urban Development (HUD), expressing our opposition to HUD’s proposed changes to the 2015 Affirmatively Furthering Fair Housing rule.

read more
March 17, 2020
An array of prescription medications on shelves

Online press briefing: Vaccines—The COVID-19 Case for Public Pharmaceutical Research and Development

Leading experts believe that it is the government’s responsibility to ensure widespread access to safe and effective vaccines that are developed with taxpayer money. In this virtual press briefing, hear why the U.S. government should develop and manufacture vaccines and other essential medicines so that we get the medicines we need, when we need them and at prices we can afford.

read more